Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
scPharmaceuticals secures $125M non-dilutive financing from Perceptive Advisors for debt repayment and FUROSCIX commercialization.
scPharmaceuticals Inc. announces an underwritten public offering of common stock or pre-funded warrants, with option for underwriters to buy 15% more within 30 days.
The company also secures up to $125M non-dilutive financing from Perceptive Advisors, a life-sciences investor.
Proceeds from both transactions will be used for debt repayment and ongoing commercialization of FUROSCIX.
4 Articles
scPharmaceuticals asegura una financiación no dilutiva de 125 millones de dólares de Perceptive Advisors para el reembolso de la deuda y la comercialización de FUROSCIX.